Roszdravnadzor confirmed high quality of Grippol® plus vaccine
Petrovax Pharm informs that an official assessment confirmed that Grippol® plus vaccine, batch No. 120814, fully complied with the quality requirements (Federal Service for Surveillance in Healthcare and Social Development (Roszdravnadzor) letter No.
Thus, Roszdravnadzor’s independent assessment and the internal investigation by Petrovax Pharm, the vaccine manufacturer, confirmed a high quality of Grippol® plus flu vaccine and the absence of causality between with vaccination and the adverse reactions in the technical college students in the Chuvash Republic.
Overall, more than 13.5 m Grippol® plus doses were successfully used in Russia in epidemiological season 2014–2015 within the framework of the National Immunization Schedule to vaccinate children and pregnant women.
